Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Dec 19, 2021 11:17pm
125 Views
Post# 34245728

RE:RE:Omicron

RE:RE:OmicronWhile I tend to agree that we should not be in an alarmist mode over Omicron until such time as we see a lot of hospitalizations occurring because of it, the math still looks worrisome even if it does not cause a lot of serious illness. That is simply because of how many people will get it. It is breaking through triple vaxed people and people who were infected before. So, there is a very good chance that most of us will end up getting an Omicron infection. If only a small percentage of those end up hospitalized, it still is going to hammer the health care systems around the world and wreak havic on the world's economy. And many hospitals are already severely overtaxed by mostly unvaxed people getting sick with the Delta variant. From a TH perspective, it could play havoc with finalizing the phase 1a and put a real kink in getting the phase 1b started. It may turn out that no interruptions in these trials are necessary but with the less than ideal way governments have handled covid so far, I would not be surprised if TH had to contend with some complications in getting these trials completed.

realitycheck4u wrote: And no one one is getting seriously ill. The percentage of double vaccinated people drying per 100000 is lower than auto accidents deaths. It's a flu. It is insane to include double or triple vax in lockdowns in any circumstance. Liberals/snowflakes/dems are bonkers

jfm1330 wrote: I fear this new variant will mess up a lot of things in the coming months. This variant is three to four times as contagious as the delta, and as virulent. We will very likely end up with shutdowns in many sectors. Here in Quebec our vaccination rate for the 12 years old and older is 90%, and this thing is rising sharply and Omicron is still not the dominant variant. So imagine in the US in many states where the vaccination rate is much lower. I fear it could be worst than the first wave.




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse